Rebus Holdings, Inc. (RBSH)

0.0001 0.0000 (0.00%) At close: 02:46PM EDT

Rebus Holdings, Inc.

2629 Townsgate Road
Suite 215
Westlake Village, CA 91361
United States
818 597 7552
https://www.rebus-corp.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Raul Silvestre Esq.	CEO, CFO, President, Principal Accounting Officer & Director	N/A	N/A	1971
Dr. John T. Isaacs Ph.D.	Co-Founder, Chairman of Scientific Advisory Board & Chief Scientific Advisor	N/A	N/A	N/A
Dr. Samuel R. Denmeade M.D.	Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.

Corporate governance

Rebus Holdings, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.